HIPROGIN 250MG INJECTION 1ML

국가: 말레이시아

언어: 영어

출처: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

유효 성분:

HYDROXYPROGESTERONE HEXANOATE/CAPROATE

제공처:

DUOPHARMA (M) SDN. BHD.

INN (국제 이름):

HYDROXYPROGESTERONE HEXANOATE/CAPROATE

패키지 단위:

10 Ampoules

Manufactured by:

DUOPHARMA (M) SDN. BHD.

환자 정보 전단

Not Applicable

제품 특성 요약

DUOPHARMA (M) SDN BHD
Page 1 of 2
[REVISION DATE: 17.08.2021]
HIPROGIN 250MG INJECTION 1ML
DESCRIPTION: Hiprogin 250mg injection 1ml: A clear yellow oily
solution for injection.
COMPOSITION:
Each ml contains Hydroxyprogesterone Caproate 250 mg.
PHARMACODYNAMICS: Progestins enter target cells by passive diffusion
and bind to cytosolic (soluble) receptors that are loosely bound in
the nucleus. The
steroid receptor complex initiates transcription, resulting in an
increase in protein synthesis.
Progestins are capable of affecting serum concentrations of other
hormones, particularly estrogen. Estrogenic effects are modified by
the progestins, either by
reducing the availability or stability of the hormone receptor complex
by turning off specific hormone-responsive genes by direct interaction
with the progestin
receptor in the nucleus. In addition, estrogen priming is necessary to
increase progestin effects by upregulating the number of progestin
receptors and/or
increasing progesterone production, causing a negative feedback
mechanism that inhibits estrogen receptors.
Depending on the progestin and its dose, progestin may demonstrate
varying degrees of progestational effects. Also, other hormonal
effects, such as
estrogenic, anabolic, androgenic, or glucocorticoid-inducing or
suppressing effects are demonstrated to different degrees and depend
on the progestin type and
dose.
Progestational agents - Progestins produce histologic changes in the
vaginal epithelium and induce secretory-like changes in the
endometrium in the second
half of the menstrual cycle. As progestin levels fall after estrogen
priming, uterine bleeding occurs.
PHARMACOKINETICS: Hydroxyprogesterone caproate is found in the blood
only 2 hours after IM administration. Maximum plasma levels are
reached on the
2
nd
day of injection. After that, the concentration decreases slowly 14
days after injection, 60% of the maximum value can still be found. The
elimination is
protracted. Hydroxyprogesterone caproate is eliminated entirely in the
form of conjugated